Does atopic dermatitis increase the risk of inflammatory bowel disease? A meta-analysis of data from 61 million participants.

Background: This review aimed to examine if atopic dermatitis (AD) led to an increased risk of inflammatory bowel disease (IBD) by collating data from longitudinal studies.

Summary: Cohort and case-control studies examining the risk of IBD, Crohn's disease (CD), or ulcerative colitis (UC) due to exposure to AD were included in this review. Articles were searched on PubMed, CENTRAL, Embase, Scopus, and Web of Science electronic repositories up to 2nd October 2024.

Exploring the pharmacological mechanism of Tripterygium wilfordii hook for treatment of Behcet's disease using network pharmacology and molecular docking.

Tripterygium wilfordii hook (TWH) has been used to treat Behcet's disease (BD) but its underlying mechanism remains unclear. This study aims to explore the mechanism of TWH on BD using network pharmacology and molecular docking. The bioactive constituents of TWH and their corresponding target genes were extracted from the Traditional Chinese Medicine systems pharmacology database and analysis platform.

Maternal exposure to antibiotics and risk of atopic dermatitis in childhood: a systematic review and meta-analysis.

Background: Although the association between maternal exposure to antibiotics and the risk of atopic dermatitis (AD) in childhood has been studied extensively, there still is a lack of clarity on the topic. The aim of this study was to summarize the published data and to examine if maternal exposure to antibiotics increases the risk of AD in childhood.

Methods: Systematic search was performed in PubMed, Scopus, Web of Science, and Embase for all types of studies on the review subject independent of any language restrictions and published up to 28th December 2022.

Off-label uses of ustekinumab.

Ustekinumab (brand name Stelara®) is a human interleukin-12 and -23 antagonist and has been indicated for the treatments of moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. This review aims to synthesize and interpret the literature evaluating the off-label uses of ustekinumab. We performed searches in PubMed and ClinicalTrials.

Histone methyltransferase EZH2 epigenetically affects CCNA1 expression in acute myeloid leukemia.

Cyclin A1 (CCNA1) is an alternative A-type cyclin that is expressed in acute myeloid leukemia (AML). However, its functions in AML cell chemoresistance, an important cause for mortality, are incompletely understood. The purpose of this study was to expound the role and potential mechanism of CCNA1 in AML cell chemoresistance.

High expression of VTRNA2-1 in systemic lupus erythematosus patients' B lymphocytes and its significance.

Objectives: To investigate the expression of vault ribonucleic acid 2-1 (VTRNA2-1) in T or B lymphocytes in patients with systemic lupus erythematosus (SLE) from the perspective of epigenetic non-coding RNA, and to explore the preliminary pathogenesis of SLE.

Methods: CD4 T lymphocytes from peripheral blood in 25 healthy controls and 32 SLE patients, CD19 B lymphocytes from peripheral blood in 62 SLE patients (47 patients were active SLE and 15 patients were inactive) and 29 healthy controls were collected, and the expression levels of VTRNA2-1 were detected by real-time PCR. Co-immunoprecipitation assay was used to explore the direct-acting proteins of VTRNA2-1.

Involvement of Populus CLEL peptides in root development.

As one of the major groups of small post-translationally modified peptides, the CLV3/EMBRYO SURROUNDING REGION-RELATED (CLE)-like (CLEL) peptide family has been reported to regulate root growth, lateral root development and plant gravitropic responses in Arabidopsis thaliana. In this study, we identified 12 CLEL genes in Populus trichocarpa and performed a comprehensive bioinformatics analysis on these genes. Among them, five P.

Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma: A systematic review and meta-analysis.

Plerixafor in combination granulocyte-colony stimulating factor (G-CSF) has been used for the mobilization of hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). The aim of this study was to systematically search the published literature and analyze evidence on the efficacy of additional plerixafor for successful HSC mobilization in patients with NHL and MM, and to evaluate the safety of the drug. The PubMed, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL) and Google scholar databases were searched electronically for studies published in the English language up to March, 2019.

Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells.

Atherosclerosis is a chronic inflammatory disease of the blood vasculature. Endothelial dysfunction is an early event in the development of atherosclerosis and the endothelium plays an important role in the innate immune defense in the pathology of cardiovascular diseases. New therapies are being developed based on the involvement of the immune system in atherosclerosis.

[Effects of Synthetic Long-Chain Polyphosphate on Blood Coagulation and Platelet Aggregation].

Objective: To investigate the effects of synthetic long-chain polyphosphate on blood coagulation and platelet aggregation.

Methods: The effect of artificial synthetic long chain poly phosphate on blood coagulation and platelet aggregation was detected by coagulation tests, coagulation factor activity detection and platelet aggregation test, and its mechanism was explored by ELISA, flow cytometry and high content imaging system.

Results: The long chain polyphosphates prolonged activated partial thromboplastin time, decreased coagulation factor FⅧ, FⅨ, FⅪ and FⅫ activity, blocked ADP-induced platelet aggregation, and decreased the concentration of calcium and TXA2 in platelet.

Cost-minimizing team hires with participation constraint.

Team formation, which aims to form a team to complete a given task by covering its required skills, furnishes a natural way to help organizers complete projects effectively. In this work, we propose a new team hiring problem. Given a set of projects [Formula: see text] with required skills, and a pool of experts [Formula: see text], each of which has his own skillset, compensation demand and participation constraint (i.

[Interpretation of the Guidance for Immune Thrombocytopenia-Review].

Since the American Medical Association published the 2011 guidelines for immune thrombocytopenia, China has been the first to update the guidelines for immune thrombocytopenia based on evidence-based medicine. Recently, there have been many breakthroughs in clinical research published, especially the Chinese medical workers have made a prominent contribution to the treatment of the immune thrombocytopenia. However, the references of systematic drug introduction for children, adults, aged and pregnant women are still insufficient, and the first or second line treatment for some patients were ineffective.

Synthetic polyphosphate inhibits endogenous coagulation and platelet aggregation .

Platelet-derived polyphosphate has previously been indicated to induce coagulation. However, industrially synthesized polyphosphate has been found to have different effects from those of the platelet-derived form. The present study investigated whether synthetic sodium polyphosphate inhibits coagulation using routine coagulation tests and thromboelastography.

IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus.

Objective: Systemic lupus erythematosus (SLE) is a clinically heterogeneous disease with limited reliable diagnostic biomarkers. We investigated whether gene methylation could meet sensitivity and specificity criteria for a robust biomarker.

Methods: IFI44L promoter methylation was examined using DNA samples from a discovery set including 377 patients with SLE, 358 healthy controls (HCs) and 353 patients with rheumatoid arthritis (RA).